ALLG is very pleased to announce the launch of the inaugural ALLG HSANZ Clinical Trials Fellowship 2024 for 2025 Award.

 

About the Fellowship Program 

The annual Fellowship Program, in partnership with the HSANZ, will provide outstanding early-career researchers a pathway to a career in clinical trial research, through engaging with ALLG trials and translational research that delivers outcomes for blood cancer patients and science.

The Fellowship will inspire and cultivate the next generation of outstanding blood cancer researchers and clinical triallists to drive better treatments and outcomes for patients with leukaemia, lymphoma, myeloma and other blood cancers.

The ALLG HSANZ Clinical Trial Fellowship is funded to a total value of $70,000 for a period of 12 months, to commence in 2025.

ALLG CEO, Delaine Smith, said “Developing better blood cancer treatments and searching for a cure takes research, time, talent and funding to make it possible.”

“To change the future for blood cancer, we must accelerate research by encouraging and directly supporting the next generation of blood cancer researchers to drive new discoveries and better treatments for patients.”

“ALLG is proud to establish this Fellowship that will enable up and coming researchers to accelerate the impact for patients through clinical trial research.”

 

How to Apply

Applications for the Fellowship are now open and will close on Sunday 28 July 2024. For more information on the ALLG HSANZ Clinical Trials Fellowship, including eligibility and how to apply, please visit www.hsanz.org.au/scholarships-and-awards.

 

Accelerate the Impact

If you would like to support this exciting initiative to accelerate the impact for patients and help ALLG to fund and equip our best and brightest blood cancer researchers, please visit www.allg.org.au/support-us/our-campaigns.